Skin Cancer Research

Skin Cancer Research

Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.

Clinical Trials

A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Exercise in Radiation Therapy (EXERT)
Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk
Physical Activity Training in Adolescents and Young Adults with Cancer: A Feasibility Study
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
A Phase III, Randomized, Open-label Study of Adjuvant Immunotherapy with'Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Participants at High ·sk for Recurrence (PIVOT-12)
The COVID-19 and Cancer Consortium (CCC19) Registry
An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Neoadjuvant Imatinib for Locally advanced Dermatofibrosarcoma Protuberans
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer
Research into skin cancer at Penn State Cancer Institute is conducted by the melanoma and skin cancer team. See current clinical trials and members of that team here.
A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Exercise in Radiation Therapy (EXERT)
Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Prognosis of Recurrence Risk
Physical Activity Training in Adolescents and Young Adults with Cancer: A Feasibility Study
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
A Phase III, Randomized, Open-label Study of Adjuvant Immunotherapy with'Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Participants at High ·sk for Recurrence (PIVOT-12)
The COVID-19 and Cancer Consortium (CCC19) Registry
An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Neoadjuvant Imatinib for Locally advanced Dermatofibrosarcoma Protuberans
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Atypical Spotzoid Melanocytic Tumors: An Institutional Review of Outcomes for an Effective Treatment
Application for Discarded Tissue From Surgery For Research Use
Definition of Somatic Variants Corresponding to Immune Targets in Patients with Metastatic Melanoma
A Retrospective Evaluation to Understand how â-adrenergic Antagonism Impacts the Progression of Melanoma and the Efficacy of Standard Treatments Intended to Eliminate the Cancer

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)